Bristol Myers Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BRISTOL MYERS, and when can generic versions of BRISTOL MYERS drugs launch?
BRISTOL MYERS has seventy-six approved drugs.
There are thirteen US patents protecting BRISTOL MYERS drugs.
There are five hundred and ninety-six patent family members on BRISTOL MYERS drugs in fifty-one countries and one hundred and forty-four supplementary protection certificates in eighteen countries.
Summary for Bristol Myers
| International Patents: | 596 |
| US Patents: | 13 |
| Tradenames: | 65 |
| Ingredients: | 58 |
| NDAs: | 76 |
| Drug Master File Entries: | 1 |
Drugs and US Patents for Bristol Myers
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | DELALUTIN | hydroxyprogesterone caproate | SOLUTION;INTRAMUSCULAR | 016911-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-003 | Jun 29, 2006 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-001 | Dec 27, 2005 | AB | RX | Yes | No | 8,741,929 | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Bristol Myers Squibb | STADOL | butorphanol tartrate | SPRAY, METERED;NASAL | 019890-001 | Dec 12, 1991 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bristol Myers Squibb | DEAPRIL-ST | ergoloid mesylates | TABLET;SUBLINGUAL | 085020-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bristol Myers Squibb | BUSPAR | buspirone hydrochloride | TABLET;ORAL | 018731-003 | Apr 22, 1996 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bristol Myers Squibb | STILBESTROL | diethylstilbestrol | INJECTABLE;INJECTION | 004056-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bristol Myers
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-003 | Jun 29, 2006 | 8,626,531 | ⤷ Try a Trial |
| Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-006 | Jun 5, 2013 | 9,056,120 | ⤷ Try a Trial |
| Bristol Myers Squibb | BUSPAR | buspirone hydrochloride | TABLET;ORAL | 018731-003 | Apr 22, 1996 | 4,215,104 | ⤷ Try a Trial |
| Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-004 | Jun 29, 2006 | 8,315,886 | ⤷ Try a Trial |
| Bristol Myers Squibb | PRAVIGARD PAC (COPACKAGED) | aspirin; pravastatin sodium | TABLET;ORAL | 021387-006 | Jun 24, 2003 | 5,180,589*PED | ⤷ Try a Trial |
| Bristol Myers Squibb | ELIQUIS | apixaban | TABLET;ORAL | 202155-001 | Dec 28, 2012 | 6,413,980 | ⤷ Try a Trial |
| Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-006 | Jun 5, 2013 | 9,101,622 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BRISTOL MYERS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 80 mg and 140 mg | ➤ Subscribe | 2011-06-17 |
| ➤ Subscribe | Delayed-release Capsules | 200 mg, 250 mg and 400 mg | ➤ Subscribe | 2004-06-01 |
| ➤ Subscribe | Capsules | 5 mg, 10 mg and 15 mg | ➤ Subscribe | 2010-08-30 |
| ➤ Subscribe | Capsules | 300 mg | ➤ Subscribe | 2009-07-20 |
| ➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2010-02-16 |
| ➤ Subscribe | Capsules | 50 mg, 100 mg and 200 mg | ➤ Subscribe | 2016-11-03 |
| ➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-06-14 |
| ➤ Subscribe | Tablets | 30 mg | ➤ Subscribe | 2005-06-01 |
| ➤ Subscribe | Tablets | 80 mg and 140 mg | ➤ Subscribe | 2011-06-16 |
| ➤ Subscribe | Capsules | 25 mg | ➤ Subscribe | 2010-07-12 |
| ➤ Subscribe | Capsules | 2.5 mg and 20 mg | ➤ Subscribe | 2016-07-12 |
| ➤ Subscribe | Capsules | 100 mg and 150 mg | ➤ Subscribe | 2010-03-19 |
| ➤ Subscribe | Tablets | 600 mg | ➤ Subscribe | 2009-04-09 |
| ➤ Subscribe | Nasal Spray | 4 mg/spray | ➤ Subscribe | 2016-07-15 |
| ➤ Subscribe | Tablets | 2.5 mg and 5 mg | ➤ Subscribe | 2016-12-28 |
| ➤ Subscribe | Tablets | 20 mg, 50 mg, 70 mg and 100 mg | ➤ Subscribe | 2010-06-28 |
International Patents for Bristol Myers Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Slovenia | 2800743 | ⤷ Try a Trial |
| Denmark | 1505973 | ⤷ Try a Trial |
| European Patent Office | 3045176 | ⤷ Try a Trial |
| Mexico | 2020011397 | ⤷ Try a Trial |
| South Korea | 101005991 | ⤷ Try a Trial |
| Hong Kong | 1091835 | ⤷ Try a Trial |
| Ukraine | 117451 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bristol Myers Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1169038 | 6/2013 | Austria | ⤷ Try a Trial | PRODUCT NAME: DASATINIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/06/363/001-015 20061120 |
| 0915894 | SPC/GB08/033 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: TENOFOVIR DISOPROXIL AND THE SALTS (IN PARTICULAR THE FUMARATE), HYDRATES, TAUTOMERS AND SOLVATES THEREOF, TOGETHER WITH EMTRICITABINE AND EFAVIRENZ; REGISTERED: UK EU/1/07/430/001 20071213; REASON FOR LAPSE: SURRENDERED |
| 0582455 | C300032 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: EFAVIRENZ; REGISTRATION NO/DATE: EU/1/99/110/001-004, EU/1/99/111/001-004 19990528 |
| 1427415 | 2011C/034 | Belgium | ⤷ Try a Trial | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGEMENT DE NOM DU PROPRIETAIRE |
| 2782584 | 21C1058 | France | ⤷ Try a Trial | PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), Y COMPRIS SOUS FORME HEMIHYDRATEE, ET DE LA PROGESTERONE; NAT. REGISTRATION NO/DATE: NL51886 20210421; FIRST REGISTRATION: BE - BE582231 20210406 |
| 2487163 | 60/2016 | Austria | ⤷ Try a Trial | PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON UND ATAZANAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE ATAZANAVIR-SULFAT; REGISTRATION NO/DATE: EU/1/15/1025 (MITTEILUNG) 20150715 |
| 1169038 | 1390004-8 | Sweden | ⤷ Try a Trial | PRODUCT NAME: DASATINIB OCH FARMACEUTISKT GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/06/363/001 20061120 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
